Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations · 5.8M shares · +64%/yr ↑ dilution · EDGAR filings ↗
Reference price $8.79 · est. market cap ~$51M — last insider purchase, 2026-03-26 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — immuno-oncology clinical (collaboration-funded), funded.
Strengths
- Liquidity — current ratio 2.6 (35th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Chronic dilutionShare count +64%/yr over 4y (dilution, book value/share -97%)
- Cash burnNegative free cash flow (-5.5M)
- Material weaknessIf we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reli
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -80.1%)
- Strong balance sheetStrong balance sheet — $138M cash & investments, ~100 quarters of runway
- Insider sellingInsider selling — 2 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
- Notable holderHeld by 3 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, FMR LLC, STATE STREET CORP (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-95.9%
Net margin
-80.1%
Return on equity
-99.3%
Return on assets
-22.6%
Revenue growth (QoQ)
-7.6%
Current ratio
2.6×
Free cash flow
-$6M
EBITDA
-$40M
Tangible book value
$35M
Cash & investments
$138M
Cash runway
100q
Stock comp / revenue
15.9%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | Buy | 5.0K | $8.79 |
| 2026-01-02 | Brennan Kevin M. | Sell | 1.8K | $0.64 |
| 2026-01-02 | Frankenfield Christopher James | Sell | 7.0K | $0.64 |
| 2026-01-01 | Luptakova Katarina | Option exercise | 17K | — |
| 2026-01-01 | Frankenfield Christopher James | Option exercise | 19K | — |
| 2026-01-01 | Russo Rene | Option exercise | 44K | — |
| 2026-01-01 | Brennan Kevin M. | Option exercise | 5.0K | — |
| 2025-06-17 | Shannon James Samuel | Buy | 25K | $0.69 |
| 2025-06-16 | Shannon James Samuel | Buy | 45K | $0.69 |
| 2025-06-16 | Russo Rene | Buy | 36K | $0.68 |
| 2025-01-02 | Brennan Kevin M. | Sell | 1.8K | $0.98 |
| 2025-01-02 | Frankenfield Christopher James | Sell | 7.0K | $0.98 |
| 2025-01-01 | Luptakova Katarina | Option exercise | 17K | — |
| 2025-01-01 | Russo Rene | Option exercise | 44K | — |
| 2025-01-01 | Brennan Kevin M. | Option exercise | 5.0K | — |
| 2025-01-01 | Frankenfield Christopher James | Option exercise | 19K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-12 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-12 | ResultsExhibits | filing ↗ |
| 2026-04-16 | Exec/director changeExhibits | filing ↗ |
| 2026-03-23 | ResultsExhibits | filing ↗ |
| 2026-03-12 | 3.035.03Exhibits | filing ↗ |
| 2026-03-09 | Reg FDExhibits | filing ↗ |
| 2026-02-24 | Shareholder vote | filing ↗ |
| 2026-02-12 | Material agreementReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-12 | 2026-06-10 | 0001193125-26-269358 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001193125-26-218194 ↗ |
| 10-Q | 2026-05-12 | 2026-03-31 | 0001193125-26-218200 ↗ |
| 8-K | 2026-04-16 | 2026-04-15 | 0001193125-26-157940 ↗ |
| 10-K | 2026-03-23 | 2025-12-31 | 0001193125-26-118550 ↗ |
| 8-K | 2026-03-23 | 2026-03-23 | 0001193125-26-118544 ↗ |
| 8-K | 2026-03-12 | 2026-03-12 | 0001193125-26-103150 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001193125-26-097603 ↗ |
| 8-K | 2026-02-24 | 2026-02-23 | 0001193125-26-065234 ↗ |
| 8-K | 2026-02-12 | 2026-02-11 | 0001193125-26-048942 ↗ |
| 8-K | 2026-01-08 | 2026-01-06 | 0001193125-26-007063 ↗ |
| 8-K | 2026-01-05 | 2026-01-05 | 0001193125-26-001580 ↗ |